SCHEMBL2239345

SCHEMBL2239345

CCCCCC(O)NC(=O)OC(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CTSK P43235 18/20 0.52
CTSS P25774 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5133847 0.98 CTSK (0.51) CTSKCTSS
SCHEMBL628885 0.95 CTSK (0.57) CTSKCTSS
SCHEMBL1843190 0.87 CTSK (0.53) CTSKCTSS
SCHEMBL1251053 0.86 TDP1 (0.53) CTSKCTSS
SCHEMBL31121751 0.84 CTSK (0.54) CTSKCTSS
SCHEMBL31121749 0.84 CTSK (0.54) CTSKCTSS
SCHEMBL7804302 0.84 TDP1 (0.50) CTSKCTSS
SCHEMBL880670 0.83 MEN1 (0.59) CTSKCTSS
SCHEMBL15015920 0.83 MEN1 (0.44) CTSKCTSS
SCHEMBL24465592 0.83 CTSK (0.56) CTSKCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8512971-B2 Compounds and methods of use thereof for assaying lysophospholipase D activity ECHELON BIOSCIENCES, INC. (US) 2013-08-20 US disclosed
US-7989663-B2 Compounds and methods of use thereof for assaying lysophospholipase D activity ECHELON BIOSCIENCES INCORPORATED (US) 2011-08-02 US disclosed
US-20100260682-A1 Compounds and methods of use thereof for assaying lysophospholipase D activity ECHELON BIOSCIENCES INCORPORATED (US) 2010-10-14 US disclosed
CN-101801429-A The immobilization on medical treatment device of dyestuff and antimicrobial BAXTER INT 2010-08-11 CN disclosed
US-20090068697-A1 Compounds and methods of use thereof for assaying lysophospholipase D activity ECHELON BIOSCIENCES INCORPORATED (US) 2009-03-12 US disclosed
US-20090024096-A1 IMMOBILIZATION OF DYES AND ANTIMICROBIAL AGENTS ON A MEDICAL DEVICE BAXTER INTERNATIONAL INC. (US) 2009-01-22 US disclosed
US-7459285-B2 Compounds and methods of use thereof for assaying lysophospholipase D activity ECHELON BIOSCIENCES INCORPORATED (US) 2008-12-02 US disclosed
US-7388112-B2 Immunomodulation with novel pharmaceutical compositions MEDIQUEST THERAPEUTICS, INC. (US) 2008-06-17 US disclosed
US-20060167054-A1 Immunomodulation with novel pharmaceutical compositions MEDIQUEST THERAPEUTICS, INC. (US) 2006-07-27 US disclosed
US-6919483-B2 Immunomodulation with novel pharmaceutical compositions MEDIQUEST THERAPEUTICS, INC. (US) 2005-07-19 US disclosed
US-20040235960-A1 Immunomodulation with novel pharmaceutical compositions MEDIQUIST THERAPRUTICS, INC. 2004-11-25 US disclosed
US-20040171096-A1 Compounds and methods of use thereof for assaying lysophospholipase D activity ECHELON BIOSCIENCES INCORPORATED 2004-09-02 US disclosed
WO-2004053459-A2 COMPOUNDS AND MEHTODS OF USE THEREOF FOR ASSAYING LYSOPHOSPHOLIPASE D ACTIVITY ECHELON BIOSCIENCES INCORPORATED (US) 2004-06-24 WO disclosed
EP-0556216-B1 PHOSPHORIC ACID ESTERS AND THEIR USE IN THE PREPARATION OF BIOCOMPATIBLE SURFACES BIOCOMPATIBLES LTD (GB) 1997-06-04 EP disclosed
US-5599587-A Phosphoric acid esters and their use in the preparation of biocompatible surfaces BIOCOMPATIBLES LIMITED (GB) 1997-02-04 US disclosed
EP-0556216-A1 PHOSPHORIC ACID ESTERS AND THEIR USE IN THE PREPARATION OF BIOCOMPATIBLE SURFACES. BIOCOMPATIBLES LTD (GB) 1993-08-25 EP disclosed
WO-1992007858-A1 PHOSPHORIC ACID ESTERS AND THEIR USE IN THE PREPARATION OF BIOCOMPATIBLE SURFACES BIOCOMPATIBLES LIMITED (GB) 1992-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090024096-A1 IMMOBILIZATION OF DYES AND ANTIMICROBIAL AGENTS ON A MEDICAL DEVICE CD99, CD44, ACR CTSK 1215/4885CTSS 449/4885
US-20090068697-A1 Compounds and methods of use thereof for assaying lysophospholipase D activity LYPLAL1, LPCAT3, LPCAT1 CTSK 240/4885CTSS 201/4885
US-20100260682-A1 Compounds and methods of use thereof for assaying lysophospholipase D activity LYPLAL1, LPCAT3, LPCAT1 CTSK 240/4885CTSS 201/4885
US-20040235960-A1 Immunomodulation with novel pharmaceutical compositions TNF, IL2, CD40 CTSK 2476/4885CTSS 1769/4885
US-20060167054-A1 Immunomodulation with novel pharmaceutical compositions TNF, IL2, CD40 CTSK 2639/4885CTSS 1336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.